Articles > Reference > Dictionaries, Thesauruses, Pictures, and Press Releases > PR Newswire UK Disclose press releases > October 2009

Article: YM BIOSCIENCES INC. - YM BioSciences announces offer.

Article from:
PR Newswire UK Disclose
Article date:
October 6, 2009
Copyright 
 
YM BIOSCIENCES ANNOUNCES OFFER FOR CYTOPIA LTD., AN AUSTRALIAN CANCER-FOCUSED 
DEVELOPMENT COMPANY 
 
MISSISSAUGA, ON, Oct. 5 /CNW/ - YM BioSciences Inc. (NYSE Amex:YMI, 
TSX:YM, AIM:YMBA), a life sciences product development company that identifies 
and advances a diverse portfolio of promising cancer-related products at 
various stages of development, today announced it has proposed to merge 
Cytopia Ltd., a clinical-stage, Melbourne-based drug development company, into 
YM. Cytopia's lead products are CYT997, a novel vascular disrupting agent 
(VDA) currently in Phase II trials, and CYT387, a novel, orally-active JAK2 
inhibitor that recently received clearance from the FDA ...

Read all of this article with a FREE trial

Related newspaper, magazine, and journal articles:

Article: YM Biosciences' subsidiary DELEX Therapeutics to ...
PR Newswire;  August 30, 2005 ;     700+ words ... ... About YM BioSciences YM BioSciences Inc. is a cancer product ... 700-patient pivotal Phase III trial in metastatic ... cancer, and for which Phase III IND applications have been filed. YM BioSciences is also developing its ... Norelin(TM), for which Phase II data have ...

Article: YM BIOSCIENCES INC. - AeroLEF(TM) phase IIb ...
PR Newswire UK Disclose;  September 27, 2006 ;     700+ words ...YM BioSciences Announces AeroLEF(TM) Phase IIb Interim Review ... Sept. 27 /CNW/ - YM BioSciences Inc. (AMEX:YMI ... advance the AeroLEF phase IIb study to full ... Chairman and CEO of YM BioSciences. "We look forward ...

Article: YM Biosciences' subsidiary DELEX Therapeutics ...
PR Newswire;  January 26, 2006 ;     700+ words ... ... addition to tesmilifene, YM BioSciences is developing nimotuzumab ... number of indications. A Phase II monotherapy trial of ... recurrent brain cancer. YM BioSciences is also developing its ... Norelin(TM), for which Phase II data have been released ...

Article: YM BIOSCIENCES INC. - Positive Phase II ...
PR Newswire UK Disclose;  October 13, 2005 ;     700+ words ...Positive Phase II prostate cancer results with YM BioSciences' lead cancer drug ... About YM BioSciences YM BioSciences Inc. is a cancer ... addition to tesmilifene YM BioSciences is developing nimotuzumab ... indications. A Phase II monotherapy trial ...

Article: YM BioSciences Initiates Patient Enrolment In ...
PR Newswire;  July 31, 2007 ;     700+ words ... ... death in non-smokers. YM BioSciences has previously announced ... Canada. Recruitment in a Phase I trial in patients ... file for two randomized Phase III trials, in grade ... 2007. Daiichi Sankyo, YM BioSciences' partner in Japan ... continues recruitment in its Phase I safety trial ...

Article: YM BioSciences starts patient treatment in ...
PR Newswire;  June 5, 2006 ;     700+ words ... ... FirstCall/ -- YM BioSciences Inc. , the cancer ... started in its Phase II trial combining ... Medical Affairs of YM BioSciences. "We expect to ... ongoing pivotal Phase III trial will ... patient pivotal Phase III trial in metastatic ... to tesmilifene, YM BioSciences is ...

Article: YM BioSciences Announces AeroLEF(TM) Phase ...
PR Newswire;  September 27, 2006 ;     700+ words ... ... FirstCall/ -- YM BioSciences Inc. , a company ... placebo-controlled Phase IIb trial (DLXLEF ... advance the AeroLEF phase IIb study to full ... Chairman and CEO of YM BioSciences. "We look forward ... pontine glioma and a Phase I/II trial in ... In addition, YM ...

Article: YM BioSciences' Lead Drug Subject of Journal ...
PR Newswire;  January 29, 2004 ;     700+ words ... ... clearance to initiate its pivotal Phase III trial for tesmilifene, also ... aggressive breast cancer. About YM BioSciences YM BioSciences Inc. is a cancer drug development ... tesmilifene, which also completed a Phase II trial in hormone refractory ...

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!

Find articles, research, and archives